Sanofi (NASDAQ:SNY) Receives Average Recommendation of “Hold” from Analysts

Sanofi (NASDAQ:SNY) has been given a consensus rating of “Hold” by the fifteen ratings firms that are presently covering the firm, Marketbeat.com reports. Ten equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and two have issued a strong buy rating on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $51.00.

SNY has been the subject of several research reports. Wall Street Zen lowered Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 21st. Weiss Ratings upgraded Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, May 13th. Citigroup reiterated a “neutral” rating on shares of Sanofi in a research note on Monday, April 13th. Argus upgraded Sanofi to a “strong-buy” rating in a research note on Monday, April 27th. Finally, Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a research note on Thursday, March 19th.

Sanofi Price Performance

NASDAQ:SNY opened at $43.55 on Wednesday. Sanofi has a 12 month low of $42.33 and a 12 month high of $53.36. The stock has a 50 day moving average of $45.55 and a two-hundred day moving average of $47.33. The company has a current ratio of 1.01, a quick ratio of 0.22 and a debt-to-equity ratio of 0.17. The firm has a market cap of $106.22 billion, a P/E ratio of 12.16, a price-to-earnings-growth ratio of 1.07 and a beta of 0.35.

Sanofi Increases Dividend

The business also recently declared an annual dividend, which will be paid on Wednesday, June 3rd. Stockholders of record on Monday, May 4th will be given a $2.4225 dividend. This represents a dividend yield of 559.0%. This is a boost from Sanofi’s previous annual dividend of $2.04. The ex-dividend date is Monday, May 4th. Sanofi’s dividend payout ratio (DPR) is currently 49.44%.

Institutional Investors Weigh In On Sanofi

Large investors have recently made changes to their positions in the stock. Flagship Harbor Advisors LLC purchased a new stake in shares of Sanofi in the fourth quarter valued at approximately $25,000. Physician Wealth Advisors Inc. grew its position in shares of Sanofi by 180.5% in the first quarter. Physician Wealth Advisors Inc. now owns 589 shares of the company’s stock valued at $28,000 after purchasing an additional 379 shares in the last quarter. Western Wealth Management LLC purchased a new stake in shares of Sanofi in the first quarter valued at approximately $29,000. Leonteq Securities AG grew its position in shares of Sanofi by 95.8% in the first quarter. Leonteq Securities AG now owns 607 shares of the company’s stock valued at $29,000 after purchasing an additional 297 shares in the last quarter. Finally, Measured Wealth Private Client Group LLC purchased a new stake in shares of Sanofi in the third quarter valued at approximately $29,000. 14.03% of the stock is currently owned by hedge funds and other institutional investors.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.